Resource impact statement
No resource impact is anticipated
We do not expect this guidance to have an impact on resources. This is because the technology is an option alongside current standard treatment options. The Department of Health and the company have agreed a patient access scheme, and the cost of treatment is anticipated to be similar to existing drugs.
This technology is commissioned by clinical commissioning groups. Providers are NHS hospital trusts.
This page was last updated: 26 October 2016